$SCLN (SciClone Pharmaceuticals, Inc.)

$SCLN {{ '2016-09-13T10:43:32+0000' | timeago}} • Announcement

$SCLN will buy 3,529,412 shares of Soligenix for $3MM. $SCLN will be responsible for development, product registration and commercialization of SGX942 in Taiwan, South Korea and Vietnam. $SCLN will pay Soligenix royalties on net sales, and Soligenix will supply drug to $SCLN on a cost-plus basis while maintaining worldwide manufacturing rights.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$GSK {{ '2017-07-21T15:28:58+0000' | timeago}} • Announcement

$GSK and $INVA announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta in patients with controlled asthma on an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA).

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$AKRX {{ '2017-07-19T21:41:28+0000' | timeago}} • Announcement

Specialty generic pharmaceutical company $AKRX said that its shareholders have voted to approve the merger for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA. The companies expect the acquisition to close by early 2018.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

$PFE {{ '2017-07-11T20:58:23+0000' | timeago}} • Announcement

The US FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of $PFE's MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate used to treat acute myeloid leukemia. The role of the ODAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve MYLOTARG is anticipated by Sept. 2017.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$CELG {{ '2017-07-06T14:11:20+0000' | timeago}} • Announcement

Upon closing of $CELG/$BGNE transaction, which is expected during 3Q17, BeiGene to receive upfront license fees of $263MM and $150MM in equity investment. BeiGene will also be eligible to receive up to $980MM in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317, a drug used to treat cancers.

$CELG {{ '2017-07-06T14:08:05+0000' | timeago}} • Announcement

$CELG enters into a collaborative agreement with biopharma company $BGNE to treat tumor cancers. Celgene will acquire 32.7MM or 5.9% of BeiGene's ordinary shares at $4.58 per share. BeiGene to acquire Celgene's commercial operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

$PFE {{ '2017-06-30T12:36:12+0000' | timeago}} • Announcement

$PFE received approval for its Besponsa as monotherapy from the European Commission. The Besponsa was approved for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). ALL is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.

$MRK {{ '2017-06-27T14:06:02+0000' | timeago}} • Announcement

$MRK provided update on Reveal outcomes study of anacetrapid. $MRK plans to review the results of the trial with external experts, and will consider whether to file new drug applications with the FDA and other regulatory agencies. The results will be presented at the European Society of Cardiology meeting on Aug. 29, 2017.

Recent Transcripts

MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 8:30pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
CELG (Celgene Corporation)
Thursday, April 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
GSK (GlaxoSmithKline plc)
Wednesday, April 26 2017 - 1:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Monday, March 6 2017 - 1:30pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm
AKRX (Akorn, Inc.)
Wednesday, March 1 2017 - 3:00pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, February 23 2017 - 9:30pm

AlphaGraphics you may like